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Abstract
A signiﬁcant inoculum-size effect has been observed with piperacillin–tazobactam, and has been associated with b-lactamase production
in extended-spectrum b-lactamase (ESBL) producers. This association has not been previously studied in the case of amoxycillin–clavula-
nate. Piperacillin–tazobactam and amoxycillin–clavulanate were compared, using high inocula of susceptible strains either harbouring
ESBLs or not. Two non-ESBL-producing and 15 amoxycillin–clavulanate-susceptible and piperacillin–tazobactam-susceptible ESBL-produc-
ing Escherichia coli isolates, and their respective transconjugants, were tested in dilution susceptibility tests using standard and 100-fold
higher inocula. Three ESBL-producing strains and E. coli ATCC 25922 were selected for time-kill studies using standard and high initial
inocula. At high inocula, MICs of piperacillin increased >eight-fold for non-ESBL-producing strains, and MICs of piperacillin–tazobactam
(8 : 1 ratio or with tazobactam ﬁxed at 4 mg/L) increased>eight-fold for all ESBL-producing strains. However, amoxycillin MICs were
not affected by a high inoculum with non-ESBL-producing strains, whereas the MICs of amoxycillin–clavulanate (2 : 1 and 4 : 1)
increased £four-fold for ESBL producers, using the broth and agar dilution methods. In kinetic studies at a high inoculum, amoxycillin
and amoxycillin–clavulanate were bactericidal against E. coli ATCC 25922, whereas piperacillin and piperacillin–tazobactam yielded
decreases of <1 log10 CFU/mL. Similarly, at a high inoculum, only amoxycillin–clavulanate was able to maintain bactericidal rates of killing
over 24 h against the ESBL-positive E. coli isolates. The stability of amoxycillin–clavulanate and the contrasting results obtained with
piperacillin–tazobactam against high inocula of ESBL-non-producing and ESBL-producing E. coli strains appear to be related to aspects
other than the amount of b-lactamase production.
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Introduction
Extended-spectrum b-lactamase (ESBL) production is consid-
ered to be one of the most important mechanisms of
resistance against b-lactams, except for carbapenems, in
Escherichia coli and Klebsiella species [1,2]. Concomitant
resistance to other antibiotics, such as ﬂuoroquinolones [3],
reduces the treatment options. ESBL-producing organisms
have frequently appeared to be susceptible to piperacillin–
tazobactam in vitro [4,5], and several authors have suggested
that this combination could be used as therapy [6,7]. How-
ever, the in vitro activity of piperacillin–tazobactam has been
called into question because of a substantial inoculum-size
effect observed in dilution susceptibility tests using ESBL pro-
ducers [8–11].
Although the available data on amoxycillin–clavulanate sus-
ceptibility of ESBL-producing strains are scarce, in some
areas this combination has been shown to be active in vitro
against 69% [12] and 85% [5] of ESBL-positive Enterobacteria-
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ceae isolates. Frequently, the recommendations concerning
the utility of b-lactams associated with b-lactamase inhibitors
are based on piperacillin–tazobatam data, but studies explor-
ing the effect of a large inoculum on amoxycillin–clavulanate
activity with ESBL producers have not been carried out.
The present study, using susceptibility tests and a time-
kill methodology, examines whether both combinations,
piperacillin–tazobactam and amoxycillin–clavulanate, behave
similarly against large inocula of non-ESBL-producing and
ESBL-producing E. coli isolates.
Materials and Methods
Strains
Tests were performed with 15 clonally unrelated piperacillin–
tazobactam-susceptible (MIC90 2 mg/L) and amoxycillin–clavul-
anate-susceptible (MIC90 4 mg/L) ESBL-producing E. coli strains
[12] that expressed sequence-conﬁrmed SHV (three SHV-12
and two SHV-2), TEM (one TEM-3, one TEM-4, one TEM-10,
one TEM-52, and one TEM-116) and CTX-M (three CTX-
M-14, one CTX-M-9, and one CTX-M-10) enzymes. Their 15
respective transconjugants, mated to E. coli J-53 AzR (resistant
to sodium azide) by conjunction [12], were also studied. Non-
ESBL-producing strains, E. coli ATCC 25922 and E. coli J-53
AzR, were included as controls.
Antimicrobial susceptibility testing
Antibiotic susceptibilities were determined using the broth
microdilution and agar dilution methods in Mueller–Hinton
broth and Mueller–Hinton agar (Oxoid, Cambridge, UK),
respectively [13]. Two different inocula were employed whose
densities differed 100-fold: 1–5 · 105 (standard inoculum) [13]
and 1–5 · 107 CFU/mL for the broth method, and 1–5 · 104
(standard inoculum) [13] and 1–5 · 106 CFU/spot for the agar
method. Tests were carried out in duplicate, and inoculum-
size controls were provided by quantitative subculture. Antibi-
otics were obtained from the following sources: amoxycillin,
piperacillin and tazobactam from Sigma-Aldrich (Madrid, Spain)
and clavulanate from GlaxoSmithKline (Brentford, UK). The
b-lactam–b-lactamase inhibitor combinations were tested as
follows: amoxycillin–clavulanate at 2 : 1 and 4 : 1, and pipera-
cillin–tazobactam at 8 : 1 with a ﬁxed concentration of 4 mg/L
tazobactam. An inoculum effect was deﬁned as an eight-fold or
greater increase in MIC value upon testing with the highest
inoculum [11].
Time-kill assays
Three clinical strains producing each type of ESBL were
selected for production of the time-kill curves, and E. coli
ATCC 25922 was included as a control. The studies
were performed at 2 ·MIC, 4 ·MIC and 8 · MIC, with initial
log-phase growth inocula of 5 · 105 (standard inoculum)
[14] and 5 · 107 CFU/mL. Amoxycillin–clavulanate was
added at a 2 : 1 ratio, and piperacillin–tazobactam was used
with a ﬁxed 4 mg/L concentration of tazobactam. Samples
were removed after 2, 4, 6, 8 and 24 h of incubation at
37C and plated using an automatic spiral spreading instru-
ment (IUL, Barcelona, Spain) for viable colony counts. The
lower limit of detection was set at log10 1.4 CFU/mL. Antibi-
otic carryover was evaluated according to CLSI guidelines
[14]. MICs of piperacillin–tazobactam were determined for
regrowth organisms.
Results
Studies with non-ESBL-producing E. coli isolates
In the case of the non-ESBL-producing strains, the MIC val-
ues of amoxycillin or the two amoxycillin–clavulanate combi-
nations were shown not to be affected by inoculum size
(Table 1). Piperacillin, however, alone or with tazobactam,
whether at a ﬁxed 4 mg/L concentration or at the ratio of
8 : 1, was associated with a pronounced inoculum effect
both in broth and in agar.
For E. coli ATCC 25922 at the standard inoculum, amoxy-
cillin and piperacillin, as well as amoxycillin–clavulanate
and piperacillin–tazobactam, were able to achieve 99.9%
killing at 8 h in time-kill studies and to maintain this over
24 h at ‡4 · MIC. With this inoculum, it appears that the
TABLE 1. MICs of b-lactams and b-lactam–b-lactamase
inhibitors for non-extended-spectrum b-lactamase-producing





S H S H
Amoxycillin Broth 4 4 2 2
Agar 4 8 2 4
Amoxycillin–clavulanate (2 : 1) Broth 4 4 2 2
Agar 4 8 2 8
Amoxicyllin–clavulanate (4 : 1) Broth 4 4 4 4
Agar 8 8 2 8
Piperacillin Broth 2 >256 1 256
Agar 2 32 0.5 16
Piperacillin–tazobactam (4 mg/L) Broth 2 256 1 256
Agar 1 32 0.5 16
Piperacillin–tazobactam (8 : 1) Broth 2 >256 1 64
Agar 2 64 0.5 16
S, standard inoculum for every method according to CLSI guidelines; H, 100-fold
standard inoculum.
CMI Lo´pez-Cerero et al. Inoculum effect on antibiotic activity 133
ª2009 The Authors
Journal Compilation ª2009 European Society of Clinical Microbiology and Infectious Diseases, CMI, 16, 132–136
two inhibitor combinations are very similar. Additionally,
when the inoculum was increased 100-fold, amoxycillin and
amoxycillin–clavulanate achieved 99.9% killing at 8 h and
24 h, whereas piperacillin and piperacillin–tazobactam
showed decreases of <1 log10 CFU/mL (Fig. 1).
Studies with ESBL-producing E. coli
Table 2 compares the variations in the MIC values of the
two b-lactam–b-lactamase inhibitors when the bacterial load
of ESBL producers was increased 100-fold. At a high inocu-
lum, a ‡8-fold increase in MIC was found for piperacillin–
tazobactam in broth (mean of 87-fold at the 8 : 1 ratio and
221-fold at 4 mg/L of tazobactam) and in agar (mean of
17-fold (8 : 1) and 168-fold (4 mg/L tazobactam)) with all the
strains. When the inoculum was increased, the MICs of
piperacillin–tazobactam were ‡256 mg/L for 90% (at the
8 : 1 ratio) and 97% (at 4 mg/L of tazobactam) of the strains.
On the other hand, neither combination of amoxycillin–
clavulanate appeared to be affected by a 100-fold inoculum
increase, the MICs increasing <8-fold in all cases with the
broth and agar methods. With the highest inoculum,
six (20%) and seven (23%) strains achieved MIC values
of 16 mg/L for amoxycillin–clavulanate 2 : 1, and 15 (50%) and
16 (53%) strains for amoxycillin–clavulanate 4 : 1, with the
FIG. 1. Time-kill curves of E. coli ATCC 25922
at high inoculum for AMC (a) and PTZ (b);
and time-kill curves of ESBL-producers at
standard inoculum with 8 · AMC MIC (c) and
· 8 PTZ MIC (d), and at high inoculum with
8 · AMC MIC (e) and 8 · PTZ MIC (f). Filled
diamonds, CTX-M-14-producing strain; open
squares, TEM-3-producing strain; open circles,
SHV-12-producing strain; double cross, 2 ·
MIC; cross, 4 · MIC; cross, 8 · MIC; broken
line, lower limit of detection.
TABLE 2. MICs of b-lactam–b-lactamase inhibitors for both clinical and transconjugant extended-spectrum b-lactamase-pro-
ducing Escherichia coli strains determined with two bacterial inocula
Type of b-lactamase
MIC (mg/L) of antimicrobial combinations
Amoxycillin–clavulanate Piperacillin–tazobactam
2 : 1 4 : 1 8 : 1 Tazobactam 4 mg/L
S H S H S H S H
CTX-M group 2–16 4–16 4–8 4–16 1–8 16 ﬁ 256 1–4 64–256
SHV group 4–16 4–16 4–16 4–16 1–16 64 ﬁ 256 1–8 64–256
TEM group 4–8 8–16 4–8 8–16 4–16 64 ﬁ 256 1–4 256
S, standard inoculum for every method according to CLSI guidelines; H, 100-fold standard inoculum.
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broth and agar methods, respectively. For no strains
were the MICs of amoxycillin–clavulanate ‡32 mg/L. No dif-
ferences were observed between clinical and transconjugant
strains.
Figure 1 shows the killing curves obtained with the three
selected ESBL-producing isolates at standard and high inocula
at antibiotic concentrations of 8 · MIC. Bactericidal results
remained similar at 2 ·MIC, 4 ·MIC, and 8 · MIC. In
standard conditions and at a high inoculum, amoxycillin–clavul-
anate achieved 99.9% killing against the three ESBL producers
at 8 h, and was able to maintain this over 24 h. The only
difference noted was with the TEM-3-producing isolate with
2 · MIC at 8 h, when amoxycillin–clavulanate achieved only
99% killing at a high inoculum. However, piperacillin–tazobac-
tam achieved maximal killing against the three ESBL producers
at 8 h, although the reduction in CFU/mL was <3 log10 at high
inoculum and regrowth occurred. No increased piperacillin–
tazobactam MIC values were observed in these cases.
Discussion
To the best of our knowledge, our results provide the ﬁrst
evidence for stability of amoxycillin–clavulanate MIC values
under an increased bacterial load of E. coli, regardless of
ESBL production or enzyme type. Additionally, we found that
a high inoculum size inﬂuences piperacillin–tazobactam and
amoxycillin–clavulanate differently in both susceptibility tests
and time-kill experiments with E. coli strains. The stability of
amoxycillin–clavulanate and the effect of inoculum size on
piperacillin–tazobactam described in this study may only
apply to E. coli. It would be interesting to investigate possible
differences in other enterobacteria.
The effects of inoculum size on piperacillin activity have
previously been investigated for non-ESBL-producing strains
using in vitro susceptibility tests [15] and for piperacilin–
tazobactam using a time-kill methodology [16]. Later studies
also noted that a large inoculum had an effect on piperacillin–
tazobactam activity with ESBL-harbouring strains. Increases
in the MIC of piperacillin–tazobactam to 256 ﬁ 512 mg/L
have been observed with TEM-producing strains [9,11] and
stains producing SHV-derived enzymes [11]. In our study, the
impact of the bacterial load affected the three ESBL types
analysed. These data agree with those of Segatore [10], who
observed a signiﬁcant inoculum-size effect with piperacillin–
tazobactam in 90% of 103 isolates producing complex
b-lactamase patterns when 5 · 108 CFU/mL was used.
The presence of an inoculum effect with piperacillin–tazo-
bactam has been associated with the production of large
amounts of hydrolysing b-lactamases derived from higher
inocula [17]. However, this does not explain amoxycillin–
clavulanate stability under the same conditions, or the results
obtained with non-producing strains. A study limitation was
the undeﬁned genetic background of the isolates that were
employed. The promoter sequences and the number of cop-
ies of the bla genes were not available, and these aspects
may modify the amount of enzyme. Nonetheless, b-lactam-
ase-producing strains behave similarly to the ATCC 25922
E. coli isolate, which lacks any enzymatic resistance determi-
nant, and therefore it is reasonable to assume that the
amount of b-lactamase, derived from a high inoculum or
from a high level of production, is not related to the inocu-
lum effect.
A potential explanation for the differences found in vitro
between piperacillin–tazobactam and amoxycillin–clavulanate,
as well as between amoxycillin and piperacillin, may depend
mainly on differences in the target protein. Amoxycillin has
the strongest afﬁnity for penicillin-binding protein (PBP) 1A
and PBP 2 [18], whereas piperacillin preferentially binds
PBP 2 and PBP 3 [19]. There is a marked decrease in PBP 3
in stationary-phase cells, because an inverse growth-depen-
dent mechanism directs the expression of this protein
(reviewed in [20]). According to our results, when large
inocula were used in the time-kill experiments, those strains
that had been incubated without an antibiotic reached the
stationary phase at 4 h. Piperacillin achieved 99.9% killing
with a standard inoculum at 6 h, and amoxycillin at 4 h. In
the in vitro conditions used in our study, large inocula may
overwhelm piperacillin, allowing growth and decreased PBP 3
production before the inhibitory activity of the antibiotic
becomes signiﬁcant. The enhanced activity of amoxycillin–
clavulanate may also be related to the modest binding of
clavulanate to PBP 2 [21]. Thus, there is an added effect on
the E. coli PBPs that is not provided by the combination with
tazobactam, an inhibitor that does not bind to E. coli PBPs.
The most important question about differences observed
in both b-lactam–b-lactamase inhibitor combinations, when
exposed to high inocula, is whether this in vitro phenomenon
may, in clinical practice, have implications for treatment.
Clinical failure has been observed for piperacillin–tazobactam
in infections caused by ESBL producers [22–24]. It would be
interesting to know whether clinical failure may occur in
serious infections with non-ESBL-producing E. coli isolates.
One way to ascertain whether in vitro differences have any
clinical signiﬁcance is through the use of an animal infection
model.
In conclusion, amoxycillin–clavulanate and piperacillin–
tazobactam behave differently against the challenge of a high
bacterial load with ESBL-producing and ESBL-non-producing
E. coli isolates. Whereas amoxycillin–clavulanate maintained
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its activity, piperacillin–tazobactam showed a pronounced
inoculum effect. Our data suggest that this inoculum effect is
not related to b-lactamase production, and further investiga-
tions are needed to ﬁnd other factors affecting the bacterici-
dal activity related to high inocula and their clinical
consequences.
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